Thermo Fisher Scientific (TMO) Research & Development (2009 - 2026)

Thermo Fisher Scientific has disclosed Research & Development across 18 years of filings, most recently posting $336.0 million for Q1 2026.

• Quarterly Research & Development fell 1.75% year-over-year to $336.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.4 billion (down 0.79% YoY) and the FY2025 annual result came in at $1.4 billion, up 0.5% from the prior year.
• Research & Development retreated to $336.0 million in Q1 2026, from $356.0 million in the prior quarter.
• Over five years, Research & Development peaked at $391.0 million in Q4 2022 and troughed at $319.0 million in Q3 2023.
• A 5-year average of $348.8 million and a median of $346.0 million in 2023 frame the typical range for Research & Development.
• Annual changes were most pronounced in 2023 — Research & Development slipped 16.37% — and 2024, when it increased 14.37%.
• Tracing TMO's Research & Development over 5 years: stood at $391.0 million in 2022, then decreased by 16.37% to $327.0 million in 2023, then grew by 14.37% to $374.0 million in 2024, then slipped by 4.81% to $356.0 million in 2025, then declined by 5.62% to $336.0 million in 2026.
• Business Quant data shows TMO's Research & Development at $336.0 million in Q1 2026, $356.0 million in Q4 2025, and $346.0 million in Q3 2025.